Connor, Clark & Lunn Investment Management Ltd. Akero Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 10,159 shares of AKRO stock, worth $286,991. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,159
Previous 69,995
85.49%
Holding current value
$286,991
Previous $1.64 Million
82.28%
% of portfolio
0.0%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$223 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$200 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$167 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$158 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$148 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.31B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...